Market Overview

UPDATE: Oppenheimer Upgraded Lannett Company and Set PT

Related LCI
A Peek Into The Markets: U.S. Stock Futures Edge Higher Ahead Of Economic Reports, Fed Speakers
Earnings Scheduled For August 23, 2017
Dow Leads Stocks As Indexes Crawl To Record Highs Again (Investor's Business Daily)

Oppenheimer analyst Rohit Vanjani Upgraded Lannett (NYSE: LCI) from Perform to Outperform and set a $29 PT following Impax Labs price boost on generic digoxin.

Vanjani downgraded Lannett two days from Outperform to Perform and removed his $20 PT a mere two days ago. In Wednesday's note, the analyst cited the company's significant outperformance. Today's note focused on Oppenheimer's confidence that the LCI price boost won't be reverted as a competitor has followed suit. The $29 PT is $5 higher than Bloomberg's average PT data.

Lannet has quadrupled Year to Date versus the Russell 2000 Health Care (RGUSHS) which is up 42 percent.

Lannett closed at $21.50 on Thursday and is currently trading +11.3 percent.

Latest Ratings for LCI

Aug 2017Deutsche BankMaintainsHold
Jul 2017Deutsche BankMaintainsHold
Aug 2016Raymond JamesMaintainsOutperform

View More Analyst Ratings for LCI
View the Latest Analyst Ratings

Posted-In: Oppenheimer Rohit VanjaniAnalyst Color Upgrades Price Target Analyst Ratings


Related Articles (LCI)

View Comments and Join the Discussion!

Partner Center